- Home
- AMAL vs BBOT Comparison
AMAL vs BBOT Comparison
Compare AMAL & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$9.01
Company Overview
Basic Information| Metric | AMAL | BBOT |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAL | BBOT |
|---|---|---|
| Price | $41.87 | $9.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $36.00 | $24.00 |
| AVG Volume (30 Days) | 112.8K | ★ 228.0K |
| Earning Date | 04-23-2026 | 05-26-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $8.08 |
| 52 Week High | $42.66 | $14.87 |
Technical Indicators
Market Signals| Indicator | AMAL | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 69.36 | 47.50 |
| Support Level | $36.56 | $8.80 |
| Resistance Level | $42.66 | $12.36 |
| Average True Range (ATR) | 0.84 | 0.57 |
| MACD | 0.37 | 0.07 |
| Stochastic Oscillator | 90.97 | 65.95 |
Price Performance
Historical Comparison AMAL
BBOT
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.